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ular symptoms (rT7SS), efficacy by disease severity and by 
predominant nasal symptom, and a set of responder analy-
ses.  Results: MP29-02 most effectively reduced rT7SS (rela-
tive greater improvement: 52% to FP; 56% to AZE) and both 
nasal and ocular symptoms irrespective of severity. More 
MP29-02 patients achieved a  ≥ 30,  ≥ 50,  ≥ 60,  ≥ 75 and  ≥ 90% 
rTNSS reduction, which occurred days faster than with either 
active comparator; MP29-02 alone was superior to placebo 
at the  ≥ 60% (or higher) threshold. One in 2 MP29-02 patients 
achieved a  ≥ 50% rTNSS reduction and 1 in 6 achieved com-
plete/near-to-complete response. Only MP29-02 was consis-
tently superior to placebo for all patients, whatever their pre-
dominant symptom.  Conclusions: MP29-02 provided faster 
and more complete symptom control than first-line thera-
pies. It was consistently superior irrespective of severity, re-
sponse criteria or patient-type, and may be considered the 
drug of choice for moderate-to-severe AR. These measures 
define a new standard for assessing relevance in AR. 
 Copyright © 2013 S. Karger AG, Basel 
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 Abstract 
 Background: It is unclear what constitutes a clinically mean-
ingful response for allergic rhinitis (AR) outcomes. The objec-
tives of these post hoc analyses were (1) to define a clinically 
meaningful response using novel efficacy analyses (includ-
ing a responder analysis), and (2) to compare the efficacy of 
MP29-02 [a novel intranasal formulation of azelastine hydro-
chloride (AZE) and fluticasone propionate (FP)] with com-
mercially available FP, AZE and placebo in seasonal AR (SAR) 
patients, using these novel analyses.  Methods: 610 moder-
ate-to-severe SAR patients ( ≥ 12 years old) were randomized 
into a double-blind, placebo-controlled, 14-day, parallel-
group trial. Change from baseline in the reflective total nasal 
symptom score (rTNSS) over 14 days was the primary out-
come. Post hoc endpoints included the sum of nasal and oc-
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 Introduction  
 The treatment of allergic rhinitis (AR) is well defined 
 [1] . Most patients seen by physicians present with moder-
ate/severe disease  [2, 3] . Treatment-resistant phenotypes 
(e.g. severe chronic upper airways disease) have been de-
scribed  [4, 5] in around 20% of treated patients. AR im-
pacts on quality of life  [6–8] and is costly  [9] . Any treat-
ment providing substantial or near-to-complete symp-
tom relief will have a considerable socioeconomic impact. 
 Intranasal corticosteroids (INS) are the most effective 
monotherapy for AR  [1, 10, 11] , but many patients are dis-
satisfied with treatment  [12] and experience breakthrough 
symptoms  [2, 3] , and consequently most patients are seek-
ing a new medication  [13] . Nasal obstruction and ocular 
symptoms represent the most bothersome symptoms  [14, 
15] and are often difficult to control. Most physicians treat 
patients using multiple therapies  [2, 3, 16, 17] to achieve 
quicker and more profound symptom relief  [18] , despite 
limited evidence to support this practice  [10, 11] . 
 Statistical significance over placebo is a proof of clini-
cal efficacy. However, clinical relevance is more difficult 
to judge, particularly when comparing active therapies, 
and cannot be expressed by a single endpoint or analysis. 
Rather, clinical relevance is influenced by patient-related 
factors such as disease severity, the predominant symp-
tom and conjunctivitis, and may be better expressed in 
terms of (1) the level of response (e.g. substantial or com-
plete); (2) the time to achieve it; (3) an assessment of ef-
ficacy in treating the entire AR symptom complex, and 
(4) efficacy assessment irrespective of disease severity or 
the predominant symptom.
 Background and Objectives 
 Scientific Background and Explanation of Rationale 
 Clinical trials should demonstrate a statistically signifi-
cant improvement in the primary efficacy endpoint, but 
clinical relevance is not readily apparent from this analysis. 
One approach is to conduct a responder analysis  [19] de-
scribed in regulatory guidelines  [20, 21] to define a level of 
response not achievable with available first-line therapy. 
 MP29-02, a novel intranasal formulation of azelastine 
hydrochloride (AZE) and fluticasone propionate (FP), 
has previously been shown to be more effective than INS 
 [22, 23] . We have taken the first of these studies, which 
compared MP29-02 to commercially available active 
comparators (i.e. Astelin ® and generic Flonase ® )  [22] to 
assess the data in a more clinically relevant way using sev-
eral new analyses. Many of these analyses had not previ-
ously been developed at the time of study protocol sub-
mission and so were introduced post hoc.
 Specific Objectives  
 This is a post hoc analysis of a phase III, multicenter, 
randomized, double-blind, parallel group trial [MP4001 
(NCT00660517)]  [22] . The aim was to firstly introduce 
new and more clinically meaningful efficacy analyses to 
gauge the efficacy of AR therapies, and secondly to assess 
the efficacy of MP29-02 and currently available first-line 
AR therapies using these new analyses. Specifically, this 
article investigates whether MP29-02 is more effective 
than commercially available active comparators (intra-
nasal AZE, Astelin; Meda Pharmaceuticals, Somerset, 
N.J., USA), generic FP nasal spray (Roxane Laboratories, 
Columbus, Ohio, USA) and placebo in controlling over-
all nasal and ocular symptoms, irrespective of baseline 
severity and in those presenting with a predominant 
symptom. A responder sensitivity analysis defined a lev-
el of response not achievable with available first-line 
therapy. These post hoc parameters were defined a prio-
ri by an independent panel of experts (including J.B., 
W.C., C.B., D.P. and others), without having access to the 
data. The methods of the study have been previously 
published  [22] and are presented in the online supple-
mentary material (for all online supplementary material, 
see www.karger.com/doi/10.1159/000351404).
 Material and Methods  
 Participants 
 Subjects ( ≥ 12 years old) with moderate-to-severe seasonal AR 
(SAR), with a minimum 2-year history, current rhinitis symptom-
atology, a positive skin prick test to mountain cedar pollen and 
who met all the study inclusion/exclusion criteria were random-
ized. 
 Planned Interventions and Timing 
 The study comprised a 7-day, single-blind, placebo lead-in
period, and a 14-day treatment period with 3 study visits on days
1, 7 and 14. On visit 2 (day 1), eligible patients were randomized
(1: 1:1: 1) to 14 days of treatment with (1) MP29-02 nasal spray [a 
novel intranasal formulation of AZE (137 μg) and FP (50 μg)]; (2) 
commercially available AZE nasal spray (137 μg); (3) commercially 
available FP (50 μg) nasal spray, or (4) vehicle placebo nasal spray. 
All sprays were given as 1 spray/nostril bid. Patients recorded symp-
tom scores in a diary and concordance with treatment was assessed.
 Efficacy Variables 
 The primary efficacy variable was change from baseline in 
morning and evening reflective total nasal symptom score 
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(rTNSS). Secondary endpoints included change from baseline in 
reflective total ocular symptom score (rTOSS), individual nasal 
and ocular symptom scores and the overall score from the 28-item 
Rhinitis Quality of Life Questionnaire (RQLQ; online suppl. text) 
 [24] .
 Sample Size, Randomization and Blinding 
 Details on sample size, randomization and blinding are pre-
sented in the online supplementary text.
 Statistical Analyses 
 Both rTNSS and rTOSS were assessed by patient severity using 
a baseline-adjusted analysis of covariance (ANCOVA) model 
(online suppl. text). Patients were categorized into two severity 
groups according to median baseline rTNSS (i.e.  ≤ 18.9 or >18.9) 
and overall RQLQ score (i.e.  ≤ 3.9 or >3.9). Those with a median 
baseline rTNSS  ≤ 18.9 or an overall RQLQ score  ≤ 3.9 were defined 
as less severe. Those patients with a median baseline rTNSS >18.9 
or an overall RQLQ score >3.9 were defined as more severe. This 
analysis is pertinent since it is important to show efficacy in pa-
tients irrespective of symptom severity. A symptomatic subgroup 
of patients was defined with rTOSS baseline  ≥ 8 to define patients 
with at least moderate ocular symptoms, since ocular symptoms 
are often not quantified even though they affect most subjects with 
SAR  [25] . A reflective total of 5 symptom scores (rT5SS; rTNSS 
plus ocular itching) and a reflective total of 7 symptom scores 
(rT7SS; rTNSS plus rTOSS) were also determined, and change 
from baseline was assessed by the same ANCOVA model, as pa-
tients frequently present to clinic with both nasal and ocular 
symptoms.
 Time to response in nasal symptoms was analyzed by Kaplan-
Meier estimates and log-rank tests. A change from baseline in 
morning and evening rTNSS of at least (1) 30, 50 [20], 60, 75 or 
90% and (2)  ≤ 1 point remaining for each symptom score (i.e. com-
plete/near-to-complete symptom resolution for both rTNSS and 
rT7SS) were used to define response. A  ≥ 50% rTNSS response was 
considered a substantial response, halving the patient’s nasal 
symptom burden. Accordingly, an rTNSS  ≥ 75% response was 
considered an extensive response representing a symptom severity 
shift in our patients from moderate/severe to mild or less. The  ≤ 1 
point score remaining for each symptom score of the rTNSS or 
rT7SS ensured complete/near-to-complete symptom relief from 
all nasal symptoms (i.e. rTNSS) or all nasal plus ocular symptoms 
(i.e. rT7SS). This criterion is extremely strict as it required that 
each nasal or each nasal plus ocular symptom was categorized as 
of less than mild severity, meaning that patients would effectively 
feel symptom free. These responder sensitivity analyses were con-
ceived in response to the EMA guideline (CHMP/EWP/2455/02) 
which questions the clinical relevance of a simple change from 
baseline in rTNSS and suggests a clinically meaningful response in 
symptom score  [20] . 
 Patients were characterized by predominant symptoms based 
on the maximum individual symptom scores at baseline (i.e. con-
gestion, itching, rhinorrhea or sneezing). rTNSS and individual 
symptom reduction were assessed in patients categorized by their 
predominant symptom to show control of the entire disease symp-
tom complex in these patients and to show relief of a patient’s par-
ticular predominant symptom. An analysis of efficacy according 
to symptom predominance is clinically relevant since patients fre-
quently present with a specific and most bothersome symptom.
 Results 
 Patients  
 The study was conducted during the 2007–2008 Tex-
as mountain cedar allergy season at 8 investigational 
sites. Six hundred and ten patients were randomized, and 
607 were included in the intend-to-treat population; 
94.6% of patients completed the study. Completion rates 
were similar across all treatment groups (online suppl. 
table  1). Baseline characteristics of the four treatment 
groups were similar (online suppl. table 2) and confirmed 
that the vast majority of these patients had moderate-to-
severe AR. 
 Outcomes 
 Original Analysis 
 MP29-02-treated patients experienced a significantly 
greater reduction in rTNSS (online suppl. fig. 1, 2), rTOSS 
and individual symptom scores compared to FP or AZE 
(online suppl. tables 3, 4) . All active treatments were well 
tolerated (online suppl. table 5).
 Post hoc Analyses 
 Rhinoconjunctivitis Symptoms (rT5SS and rT7SS) 
 MP29-02 patients had a significantly greater reduction 
in rT5SS and rT7SS than those treated with FP or AZE 
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 Fig. 1. Effect of MP29-02 (blue), FP (red), AZE (green) and pla-
cebo (yellow) on least squares (LS) mean change from baseline in 
rT7SS by treatment day (numbers and baseline data are provided 
in online suppl. table 6).  *  p  ≤ 0.0336 vs. MP29-02.  
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monotherapies (online suppl. table 6). For rT7SS there 
was a relative greater improvement of 52 and 56% com-
pared to FP (p = 0.0013) and AZE (p = 0.0004), respec-
tively. The benefit was observed during the first day of 
treatment and was sustained over the entire course of 
treatment ( fig. 1 ). 
 Reflective Total Nasal Symptom Score Change from 
Baseline Considering Severity 
 MP29-02 was significantly superior to both FP and 
AZE in alleviating patients’ overall nasal symptoms re-
gardless of disease severity (online suppl. table  6). For 
patients with less severe disease (median baseline rTNSS 
 ≤ 18.9) the relative difference with MP29-02 was 42% 
compared to FP (p = 0.0188) and 64% compared to AZE 
(p = 0.0002), which increased to 49% (p = 0.0436) and 
70% (p = 0.0035), respectively, for those with more severe 
disease (median baseline rTNSS >18.9; online suppl. 
fig. 3). 
 Reflective Total Ocular Score Change from Baseline 
Considering Severity  
 In patients with moderate-to-severe ocular symptoms 
at baseline (i.e. those with a median baseline rTOSS  ≥ 8), 
MP29-02 was significantly superior to both FP and AZE, 
with a relative difference of 63% versus FP and 42% versus 
AZE (p = 0.0012 and p = 0.0456; online suppl. table 6; on-
line suppl. fig. 3). 
 rTNSS Responder Analyses 
 For all response cutoffs (i.e.  ≥ 30,  ≥ 50,  ≥ 60,  ≥ 75 and 
 ≥ 90% response), more MP29-02 patients achieved these 
rTNSS reductions and did so days faster than both active 
comparators and placebo patients ( table  1 ;  fig.  2 ). The 
fraction of responders decreased when stricter response 
criteria were chosen, but the respective differences be-
tween MP29-02 and active comparators became more ap-
parent ( table 1 ). For the  ≥ 60,  ≥ 75 and  ≥ 90% rTNSS re-
duction only MP29-02 could be statistically differentiated 
from placebo ( table 1 ;  fig. 2 ). 
 For the criterion of  ≤ 1 point remaining in each nasal 
symptom score, 17.8% (or 1 in 6) of MP29-02 patients 
had a complete/near-to-complete nasal symptom resolu-
tion versus 9.2% of FP patients, 8.3% of AZE patients and 
7.8% of placebo patients ( fig.  2 ). MP29-02 patients 
achieved this response up to 8 days faster than either FP 
(p = 0.0262) or placebo (p = 0.0094) and up to 7 days 
faster than AZE (p = 0.0152). For the strictest response 
criterion of  ≤ 1 point remaining for all symptoms (rT7SS), 
14.2% (or 1 in 7) of MP29-02 patients achieved complete/
Table 1.  rTNSS response sensitivity analysis showing the proportion of patients achieving each response (at day 14) and the advantage 
(in days) of MP29-02 over active comparators and placebo
Response criteria1 MP29-02 AZE FP Placebo
≥30% reduction in rTNSS
Patients at day 14, %
Advantage of MP29-02, days 
71.2 65.5
≤5 (p = 0.1025)*
61.1
≤7 (p = 0.0225)*
47.2
≤10 (p<0.0001)
≥50 reduction in rTNSS
Patients at day 14, %
Advantage of MP29-02, days
49.1 37.4
≤6 (p = 0.0223)
38.2
≤6 (p = 0.0284)*
28.3
≤10 (p<0.0001)
≥60% reduction in rTNSS
Patients at day 14, %
Advantage of MP29-02, days
35.6 26.0
≤8 (p = 0.0404)
25.1
≤7 (p = 0.0496)
20.9
≤10 (p = 0.0029)
≥75% reduction in rTNSS
Patients at day 14, %
Advantage of MP29-02, days
25.5 16.4
≤8 (p = 0.0242)
17.7
≤7 (p = 0.0848) 
12.9
≤9 (p = 0.0032)
≥90% reduction in rTNSS
Patients at day 14, %
Advantage of MP29-02, days
14.5 3.5
≤8 (p = 0.001)
5.4
≤6 (p = 0.012)
6.0
≤9 (p = 0.0126)
 Bold data represent significance vs. placebo. * p < 0.05 vs. placebo derived by log-rank tests. Significance values provided are vs. 
MP29-02. Data in italics denote significance vs. placebo where lost.
1 Derived by Kaplan-Meier curves estimating time to first response and considering censored data; days advantage refer to the max-
imal horizontal distances in the Kaplan-Meier curves.
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near-to-complete elimination from all their nasal and oc-
ular symptoms compared to 8.5% of FP patients, 6.2% of 
AZE patients and 5.7% of placebo patients, achieving this 
response up to 8 days faster than patients in the FP (p = 
0.0929), AZE (p = 0.0204) or placebo groups (p = 0.0123; 
 fig. 2 ).
 Predominant Symptom 
 Only MP29-02 was consistently statistically superior 
to placebo in reducing rTNSS for all patient types, what-
ever their leading symptom ( table 2 ). FP was no better 
than placebo in reducing rTNSS for patients whose pre-
dominant symptom was nasal itching ( table  2 ). Com-
pared to FP, MP29-02 provided significantly better rTNSS 
reduction for those patients mainly suffering from con-
gestion (online suppl. fig. 4), nasal itching or sneezing. 
Compared to AZE, MP29-02 provided superior rTNSS 
reduction in those patients for whom congestion (online 
suppl. fig. 4) and rhinorrhea were the primary complaint.
 Only MP29-02 consistently and significantly reduced 
the individual nasal symptom score compared to placebo 
corresponding to patients’ predominant symptom (with 
the exception of nasal itching; p = 0.0657;  table  3 ). By 
comparison, FP was no more effective than placebo in al-
leviating nasal congestion or nasal itching in patients pre-
senting with these symptoms predominantly. MP29-02 
was significantly superior to FP in relieving nasal conges-
tion (online suppl. fig. 4), itching and sneezing in patients 
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 Fig. 2. Time to response curves following treatment for 14 days with MP29-02 (blue), FP (red), AZE (green) and 
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for whom these were the predominant symptoms. MP29-
02 was also superior to AZE in relieving congestion (on-
line suppl. fig. 4) and rhinorrhea in patients most both-
ered by these symptoms ( table 3 ).
 Discussion 
 MP29-02, a novel intranasal formulation of AZE and 
FP, is more effective than commercially available active 
comparators in providing relief from all symptoms, in-
cluding ocular ones. The responder sensitivity analysis 
showed that more MP29-02 patients achieved each and 
every response threshold and did so days faster than in-
tranasal FP or AZE, an important consideration since a 
typical moderate-to-severe SAR episode lasts 12.5 days 
on average  [18] . MP29-02 also provided the greatest re-
lief, irrespective of disease severity, most effectively treat-
ed the entire nasal and ocular symptom complex, and tar-
geted patients’ most bothersome symptoms.
 In this paper we define several new analyses which per-
mit assessment of clinical relevance of treatments for the 
first time in AR. Regulatory authorities suggest measuring 
response to treatment using a responder analysis to dem-
onstrate the magnitude of clinical effect  [20, 21] , but they 
are seldom reported. Here we assess clinically relevant re-
sponse using novel time to response sensitivity analyses 
which included both relative and absolute response crite-
ria. Both are important to patients, since the former as-
sesses a clinically relevant response from baseline (e.g. a 
Table 2.  Reduction in overall nasal symptom score (rTNSS) by patient type
Treatment Baseline
rTNSS1
LS mean
CFB
Relative
difference2
Absolute difference 95% CI p value
rTNSS change from baseline in those patients whose predominant symptom is nasal congestion
MP29-02 (n = 98) 19.56 (2.89) –5.64 – – – – –
FP (n = 84) 18.57 (3.95) –3.93 57% MP–FP –1.71 –3.00, –0.43 0.0093
AZE (n = 93) 18.20 (3.87) –3.28 79% MP–AZE –2.36 –3.51, –1.21 <0.0001
PLA (n = 93) 18.85 (3.60) –2.63 – MP–PLA –3.01 –4.14, –1.88 <0.0001
FP–PLA –1.30 –2.51, –0.09 0.0356
AZE–PLA –0.65 –1.69, 0.39 0.2185
rTNSS change from baseline in those patients whose predominant symptom is nasal itching
MP29-02 (n = 40) 20.09 (3.36) –5.48 – – – – –
FP (n = 45) 20.56 (3.06) –3.01 100% MP–FP –2.47 –4.24, –0.69 0.0072
AZE (n = 45) 18.83 (3.77) –3.80 68% MP–AZE –1.68 –3.55, 0.19 0.0781
PLA (n = 46) 20.63 (3.26) –3.02 – MP–PLA –2.46 –4.27, –0.64 0.0088
FP–PLA 0.01 –1.30, 1.32 0.9866
AZE–PLA –0.78 –2.29, 0.73 0.3096
rTNSS change from baseline in those patients whose predominant symptom is rhinorrhea
MP29-02 (n = 41) 20.09 (3.55) –5.46 – – – – –
FP (n = 45) 19.50 (3.43) –4.89 17% MP–FP –0.57 –2.31, 1.16 0.5131
AZE (n = 38) 19.89 (3.60) –3.65 55% MP–AZE –1.81 –3.44, –0.19 0.0294
PLA (n = 40) 19.91 (3.72) –2.19 – MP–PLA –3.27 –4.89, –1.65 0.0001
FP–PLA –2.70 –4.30, –1.11 0.0011
AZE–PLA –1.46 –2.89, –0.03 0.0456
rTNSS change from baseline in those patients whose predominant symptom is sneezing
MP29-02 (n = 25) 19.36 (4.19) –5.21 – – – – –
FP (n = 27) 19.59 (4.06) –2.96 51% MP–FP –2.25 –4.05, –0.44 0.0154
AZE (n = 22) 20.38 (3.52) –4.46 17% MP–AZE –0.75 –2.66, 1.17 0.4401
PLA (n = 24) 20.35 (3.78) –0.84 – MP–PLA –4.37 –6.12, –2.62 <0.0001
FP–PLA –2.12 –3.85, –0.40 0.0167
AZE–PLA –3.62 –5.34, –1.91 <0.0001
PLA = Placebo; LS = least squares; CFB = change from baseline; CI = confidence interval.
1 Mean (SD); maximum baseline rTNSS = 24. 
2 [1 – (FP or AZE – PLA)/(MP29-02 – PLA)] × 100. 
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halving of symptom burden) and the later defines the 
symptoms remaining after treatment. Since clinical rele-
vance is also influenced by patient-related factors such as 
disease severity, the predominant symptom and the pres-
ence of comorbidity, we also assessed efficacy in those pa-
tients with more and less severe disease, in those present-
ing with a predominant symptom, as well as the ability to 
treat the overall rhinitis symptom complex, incorporating 
the nasal and ocular symptoms most commonly associ-
ated with rhinoconjunctivitis. The only study to compare 
MP29-02 to commercially available active comparators 
was chosen to test these new efficacy analyses in order to 
ensure relevance to the real-world situation.
 These analyses add important information not previ-
ously published  [22] . A recent publication by Carr et al. 
 [23] on a different set of patients and using active com-
parators not commercially available also showed the 
treatment effect and consistent response of MP29-02 
across seasons, symptoms and severity. However, treat-
ment differences presented in that meta-analysis  [23] 
were consistently less than those presented here, since the 
effect of formulation and device were eliminated. 
 Although the responder and other post hoc analyses 
reported here were not primary objectives of the trial, 
these parameters were defined as important by an inde-
pendent panel of experts without having access to the 
data. The sensitivity analysis from  ≥ 30 to  ≥ 90% rTNSS 
reduction from baseline incorporated a full range of im-
provement (from marginal to very important). One in 2 
MP29-02 patients achieved the substantial response of 
Table 3.  Reduction in individual nasal symptom scores by patient type
Treatment Baseline
symptom score1
LS mean
CFB
Relative
difference2
Absolute difference 95% CI p value
Change from baseline in nasal congestion score for those patients whose predominant symptom is nasal congestion
MP29-02 (n = 98) 5.60 (0.47) –1.41 – – – – –
FP (n = 84) 5.34 (0.78) –0.90 71% MP–FP –0.51 –0.83, –0.19 0.0018
AZE (n = 93) 5.36 (0.77) –0.83 81% MP–AZE –0.58 –0.88, –0.29 0.0001
PLA (n = 93) 5.47 (0.65) –0.69 – MP–PLA –0.72 –1.02, –0.42 <0.0001
FP–PLA –0.21 –0.50, 0.09 0.1641
AZE–PLA –0.14 –0.40, 0.12 0.2894
Change from baseline in nasal itching score in those patients whose predominant symptom is nasal itching
MP29-02 (n = 40) 5.56 (0.60) –1.37 – – – – –
FP (n = 45) 5.59 (0.57) –0.78 123% MP–FP –0.59 –1.08, –0.09 0.0214
AZE (n = 45) 5.35 (0.75) –1.15 47% MP–AZE –0.22 –0.75, 0.31 0.4042
PLA (n = 46) 5.64 (0.61) –0.90 – MP–PLA –0.47 –0.98, 0.03 0.0657
FP–PLA +0.11 –0.23, 0.46 0.5158
AZE–PLA –0.25 –0.66, 0.16 0.2300
Change from baseline in rhinorrhea score in those patients whose predominant symptom is rhinorrhea
MP29-02 (n = 41) 5.57 (0.64) –1.50 – – – – –
FP (n = 45) 5.42 (0.63) –1.46 6% MP–FP –0.04 –0.57, 0.49 0.8671
AZE (n = 38) 5.49 (0.68) –1.03 58% MP–AZE –0.48 –0.94, –0.02 0.0424
PLA (n = 40) 5.49 (0.69) –0.67 – MP–PLA –0.83 –1.32, –0.34 0.0012
FP–PLA –0.78 –1.29, –0.28 0.0029
AZE–PLA –0.35 –0.77, 0.07 0.0992
Change from baseline in sneezing score in those patients whose predominant symptom is sneezing
MP29-02 (n = 25) 5.27 (0.87) –1.89 – – – – –
FP (n = 27) 5.33 (0.82) –0.98 61% MP–FP –0.91 –1.40, –0.43 0.0004
AZE (n = 22) 5.45 (0.68) –1.47 28% MP–AZE –0.42 –0.94, 0.09 0.1065
PLA (n = 24) 5.38 (0.79) –0.40 – MP–PLA –1.49 –1.95, –1.04 <0.0001
FP–PLA –0.58 –1.02, –0.14 0.0101
AZE–PLA –1.07 –1.51, –0.64 <0.0001
 PLA =  Placebo; LS = least squares; CFB = change from baseline; CI = confidence interval.
1 Mean (SD); maximum symptom score = 6. 
2 [1 – (FP or AZE – PLA)/(MP29-02 – PLA)] × 100.
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halving their nasal symptom burden (i.e.  ≥ 50%) and 1 in 
4 MP29-02 patients had mild or less symptoms after treat-
ment (i.e.  ≥ 75% reduction in rTNSS) achieved days fast-
er than with either active comparator. 
 The analysis showed the significant advantage of 
MP29-02 over the most effective medication class cur-
rently available to treat AR (i.e. INS) and also the re-
sponder criterion at which INS cease to benefit patients 
over the placebo response (i.e.  ≥ 60% rTNSS reduction 
from baseline). More MP29-02 patients also achieved the 
absolute response criterion of complete/near-to-com-
plete nasal symptom resolution, which is clinically rele-
vant considering both the severity of the patient popula-
tion (i.e. rTNSS  ≥ 8/12 and nasal congestion  ≥ 2/3) and 
the strictness of the complete/near-to-complete criterion 
which means patients have less than mild symptoms 
across the rhinitis symptom complex spectrum. This was 
not the case with INS which did not differ from placebo 
in this regard. 
 In clinical practice, patients frequently present with a 
predominant symptom. Congestion is frequently report-
ed as the most bothersome nasal symptom  [15] . Not only 
was MP29-02 more effective than FP or AZE at providing 
targeted symptom relief per patient ‘type’ (e.g. more ef-
fectively reduced nasal congestion in patients whose pre-
dominant symptom was nasal congestion), it did so whilst 
maintaining overall control of the nasal symptom com-
plex in all patient types. For nasal congestion-predomi-
nant patients, MP29-02 effectively reduced this symptom 
and patients’ overall rTNSS, and thus may reduce the 
need for a nasal decongestant prior to MP29-02 adminis-
tration. 
 However, for some patients the most bothersome 
symptoms of AR are from ocular origin  [14, 17] , which 
are usually less well controlled than nasal symptoms  [26, 
27] . Intranasal fluticasone furoate controls ocular symp-
toms  [28] , but its real efficacy compared to other INS is 
unclear since no head-to-head comparison has been 
made, and other INS also have some effect on these symp-
toms  [29] . It cannot, therefore, be proposed that one INS 
is more effective than another. A novel treatment which 
more effectively controls ocular symptoms fills the gap 
for an important unmet need in AR. MP29-02 was clear-
ly better at reducing ocular symptoms than FP and also 
AZE.
 This clinical study did not include patients with mild 
AR who frequently self-medicate and are rarely seen in a 
clinic, but rather included patients with moderate-to-se-
vere AR who represent the patient population most seen 
by GPs or respiratory specialists. The generalizability of 
these data is an inherent limitation of all randomized tri-
als  [30] since inclusion and exclusion criteria has to be in 
agreement with FDA and EMA guidelines. However, the 
results of FP are representative for the entire class of INS, 
since FP and fluticasone furoate  [31] and FP and mo-
metasone furoate  [32] have shown comparable efficacy in 
direct comparison studies. 
 MP29-02 has an excellent safety profile. Data captured 
from 4,022 patients recruited into four 14-day SAR stud-
ies confirmed that treatment-related adverse events 
(TRAEs) observed were those usually reported with AZE 
(dysgeusia) and FP (headache and epistaxis), did not ex-
ceed placebo in many instances and were ‘mild’ in the vast 
majority of cases  [22, 23] . Furthermore, in a long-term 
(52-week) study in patients with chronic rhinitis the in-
cidence of TRAEs was low, with no evidence of accumu-
lation of TRAEs over time or evidence of cortisol suppres-
sion. Additionally, no nasal mucosal ulceration or perfo-
rations were seen and ocular examination findings were 
unremarkable  [33] .
 MP29-02 also provided significant benefit over FP and 
AZE in reducing patients’ global and individual nasal or 
ocular symptoms. The clinical benefit of MP29-02 was 
observed during the first day of assessment and was sus-
tained over the entire course of treatment. This post hoc 
analysis may help physicians to better assess patients’ 
phenotypes for treatment. Taken together, MP29-02 may 
be considered the drug of choice for moderate-to-severe 
AR patients. These measures could define a new standard 
for assessing clinical relevance in AR.
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